Home » Study Verifies Potential for Monitoring Metastatic Breast Cancer with Cell-Free DNA in Blood

Study Verifies Potential for Monitoring Metastatic Breast Cancer with Cell-Free DNA in Blood

Mar 14, 2013
|
Andrea Anderson

NEW YORK (GenomeWeb News) – A proof-of-principle study appearing online last night in the New England Journal of Medicine suggests that circulating, cell-free DNA can serve as an effective blood-based marker for monitoring metastatic breast cancer in women undergoing treatment for the disease.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Related Articles

Oct 01, 2014

With $6.5M in Funding, Inivata Seeks Partners to Test Liquid Biopsy Approach for Cancer

Premium
Nov 25, 2014

Exosome Dx Presents Data on New Combined Exosomal RNA and ctDNA Liquid Biopsy Platform

Premium
Sep 23, 2014

Inivata Raises $6.6M to Develop ctDNA Assays

Apr 30, 2014

MDx/CDx Focus: CHMP Recommends Mekinist; Biocept Launches Biomarker Research Services for Pharma

Premium
Sep 10, 2014

Cynvenio Looks to Add Cell-free DNA Analysis to Circulating Tumor Cell Platform

Premium
Feb 20, 2015

Guardant Health, Collaborators Present Clinical Validity Data for ctDNA Assay

Premium

The Scan

This Week in Genome Research

In Genome Research this week: multiplex genotyping of germline and somatic short tandem repeats, graph-based regularization, and more.

To the Brink

A lack of funding may lead more than two dozen research facilities in Australia to shut down in three months.

Just Like Your Old Pop

Researchers report that paternally inherited genes are more likely to be expressed in mice.

What We'd Do With the Money

National Institutes of Health Director Francis Collins appears before a House subcommittee to discuss his agency's budget request.

What's Popular?

In Clinical Sequencing

  1. Sequenom Posts 13 Percent Rise in Q4 Revenues, Reports Profitability for FY 2014

  2. Baylor Aims to Boost Dx Rate, Discovery with 'Medical Exome,' Consenting Unsolved Cases for Research

    Premium

  3. AGBT: WashU Applies Genomic Testing to Predict Cancer Relapse, Drug Response, Vaccine Epitopes

    Premium

  4. International Team Sequences Seaweed Genome

  5. Companies Increasingly Aim to Tap into Growing Liquid Biopsy Market

    Premium

Sponsorships

Privacy Policy.  Copyright © 2015 Genomeweb LLC.  All Rights Reserved.